Mr. Robert Thast reports

IZOTROPIC EXECUTES FORMAL AGREEMENT WITH IZOTROPIC AFRICA FOR EXCLUSIVE DISTRIBUTION THROUGHOUT AFRICA AND THE GCC

Further to Izotropic Corp.'s April 29, 2026 announcement, it has executed the formal agreement with Izotropic Africa (IZAF), together with the distribution agreement and shareholders' agreement, establishing the definitive commercial, operational and governance framework for the commercialization of IzoView throughout Africa and the Gulf Cooperation Council (GCC).

The formal agreement finalizes the ownership of Izotropic Africa, with 51 per cent owned by IZAF shareholders and 49 per cent owned by Izotropic, and appoints IZAF as Izotropic's exclusive distributor and commercialization partner throughout the territory. The increased ownership interest held by Izotropic reflects the significant strategic opportunities developing throughout Morocco and the territory, and the company's expanded commitments to the long-term development, commercialization and growth of IZAF.

The formal agreement has an initial five-year term and provides for an initial five-year period of distribution exclusivity commencing upon the first commercial installation within the territory. Distribution exclusivity is maintained throughout the initial exclusivity period by the continued achievement of the established minimum performance requirements. The formal agreement will automatically renew for successive one-year terms, provided IZAF continues to satisfy the established performance requirements and remains in compliance with the formal agreement, while positioning IZAF to become eligible for exclusive commercialization and distribution rights in additional territories and for future products and technologies that may become available under the formal agreement.

Under the terms of the formal agreement, IZAF will be responsible for sales, marketing, customer development, government and Ministry of Health engagement, regulatory support, installation, technical support, service, maintenance, and continuing customer operations. The agreement initially covers the commercialization of IzoView together with associated software, accessories, replacement components, related services, and future products and technologies. Izotropic retains responsibility for manufacturing, product development, engineering, scientific, technical and clinical support, regulatory oversight, software management, quality systems, and life cycle management, while continuing to retain ownership and control of its intellectual property, regulatory assets, software, trademarks, future technologies, product improvements, and other proprietary rights associated with the IzoView platform.

The shareholders' agreement establishes the ownership and governance arrangements applicable to IZAF. Certain provisions have been intentionally reserved for future determination and will be completed by an amendment following the conclusion of certain material developments currently under way that are expected to influence those provisions. The parties do not expect this to impact the continuing governance or business activities of IZAF.

With the formal agreement now in place, IZAF will proceed with the expansion of regulatory submissions across key jurisdictions in the territory, deployment of initial clinical and demonstration systems, acceleration of hospital onboarding and pilot site activation, formalization of government and institutional partnerships, advancement of manufacturing and regional assembly feasibility studies, and scaling of commercial pipelines across priority markets.

Mohammed Sair, general manager, IZAF, comments:

"We are proud to reach this strategic milestone with Izotropic Corp. This formal agreement constitutes a solid foundation for the development of Izotropic's activities in Morocco, Africa and the Gulf Cooperation Council countries.

"In Morocco, where we are currently hosting Izotropic management, we are actively pursuing the necessary regulatory procedures to prepare for the introduction of Izotropic's technologies to the market. In this context, we have initiated the process of preparing a research dossier in collaboration with the AMMPS in Morocco. In parallel, we have engaged leading health care institutions for future clinical evaluations, while strengthening relationships with major hospital groups across Africa and the GCC.

"We are also advancing discussions with industrial partners, strategic investors and funding institutions regarding the establishment of a high-technology manufacturing facility in Morocco. This initiative is aligned with a long-term vision to position Morocco as a regional hub for production, distribution and technical support for Izotropic's advanced breast imaging solutions.

"We are confident that this collaboration will improve access to next-generation medical technologies and strengthen health care capacity across the region."

We seek Safe Harbor.